Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Deloitte
Merck
Chinese Patent Office
Fish and Richardson
Novartis
Argus Health
Fuji
Baxter
Queensland Health

Generated: August 20, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:Zinc-free and low-zinc insulin preparations having improved stability
Abstract:The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin metabolite, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent, a buffer or an excipient, wherein the formulation is free from or low in zinc. The invention also relates to the production of such insulin preparations and their use as pharmaceutical formulations.
Inventor(s): Boderke; Peter (Frankfurt am Main, DE)
Assignee: Sanofi-Aventis Deutschland GmbH (Frankfurt am Main, DE)
Application Number:11/683,747
Patent Claims: 1. A formulation comprising per milliliter: (a) 1.4 to 35 mg of Lys(B3), Glu(B29) human insulin; (b) 10 to 100 .mu.g of polysorbate 20; (c) 1 to 5 mg m-cresol; (d) 5 to 7 mg of tromethamine; (e) 1 to 8 mg NaCl; and (f) water; wherein the formulation is free from zinc or contains less than 0.2% by weight of zinc based on the insulin content of the formulation; and wherein the pH of the formulation is 7.3+/-0.2.

2. A formulation comprising per milliliter: (a) 3 to 5 mg of Lys(B3), Glu(B29) human insulin; (b) 10 to 100 .mu.g of polysorbate 20; (c) 1 to 5 mg m-cresol; (d) 5 to 7 mg of tromethamine; (e) 1 to 8 mg NaCl; and (f) water; wherein the formulation is free from zinc or contains less than 0.2% by weight of zinc based on the insulin content of the formulation; and wherein the pH of the formulation is 7.3+/-0.2.

3. A formulation comprising per milliliter: (a) 3 to 4 mg of Lys(B3), Glu(B29) human insulin; (b) 0.01 mg of polysorbate 20; (c) 3.15 mg m-cresol; (d) 6 mg of tromethamine; (e) 5 mg NaCl; (f) water; wherein the formulation is free from zinc or contains less than 0.2% by weight of zinc based on the insulin content of the formulation; and wherein the pH of the formulation is 7.3+/-0.2.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Cipla
Dow
Accenture
Cantor Fitzgerald
Deloitte
Moodys
US Army
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot